DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
keyhole limpet hemocyanin is an investigational drug.
There have been 29 clinical trials for keyhole limpet hemocyanin. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 1996.
The most common disease conditions in clinical trials are Glioblastoma, Lymphoma, and Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), and John Sampson.
Recent Clinical Trials for keyhole limpet hemocyanin
|A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma||Mount Sinai Hospital, New York||Phase 2|
|A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma||New York University School of Medicine||Phase 2|
|Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant||PCI Biotech AS||Phase 1|